Levodoxazosin Mesylate

甲磺酸左旋多沙唑嗪

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLevodoxazosin Mesylate
Drug Alias NameNCPC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptor alpha-1 antagonists
TargetsAdrenergic receptors alpha-1
Therapy Area/IndicationsProstatic Hyperplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNorth China Pharmaceutical Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNorth China Pharmaceutical Group New Drug R&D Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Hyperplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A